Mapping functional residues onto integrin crystal structures

Current Opinion in Structural Biology

Volumn 13, Issue 2, 2003, Pages 236-243

  Humphries, Martin J ^a   Symonds, Emlyn J H ^a   Mould, A Paul ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; EPIDERMAL GROWTH FACTOR; EPITOPE; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LIGAND; MONOCLONAL ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

BINDING SITE; CRYSTAL STRUCTURE; LIGAND BINDING; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

EID: 0037397574     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(03)00035-6     Document Type: Review

References (50)

1. Lee J.O., Rieu P., Arnaout M.A., Liddington R. Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). Cell. 80:1995;631-638.
2. Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., Joachimiak A., Goodman S.L., Arnaout M.A. Crystal structure of the extracellular segment of integrin αVβ3. Science. 294:2001;339-345 This is the first report of the crystal structure of a full-length extracellular integrin dimer. The coordinates provide the structural template onto which functional sites are mapped in this article.
3. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Arnaout M.A. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science. 296:2002;151-155 This is the first report of the crystal structure of a full-length extracellular integrin dimer complexed with a ligand. The RGD contact sites validate much of the data described in this review.
4. Arnaout M., Goodman S., Xiong J. Coming to grips with integrin binding to ligands. Curr. Opin. Cell Biol. 14:2002;641-651.
5. Shimaoka M., Takagi J., Springer T.A. Conformational regulation of integrin structure and function. Annu. Rev. Biophys. Biomol. Struct. 31:2002;485-516.
6. Hynes R. Integrins: bidirectional, allosteric signaling machines. Cell. 110:2002;673-687.
7. Liddington R.C., Ginsberg M.H. Integrin activation takes shape. J. Cell Biol. 158:2002;833-839.
8. Humphries MJ, McEwan PA, Askari JA, Barton SJ, Buckley PA, Craig SE, Bella J, Mould AP: Integrin structure: heady advances in ligand binding, but activation makes the knees wobble. Trends Biochem Sci 2003, in press.
9. Humphries M.J. Integrin structure. Biochem. Soc. Trans. 28:2000;311-339.
10. Hogg N., Bates P.A. Genetic analysis of integrin function in man: LAD-1 and other syndromes. Matrix Biol. 19:2000;211-222.
11. French D.L. The molecular genetics of Glanzmann's thrombasthenia. Platelets. 9:1998;5-20.
12. Calvete J.J., Arias J., Alvarez M.V., Lopez M.M., Henschen A., Gonzalez-Rodriguez J. Further studies on the topography of the N-terminal region of human platelet glycoprotein IIIa. Localization of monoclonal antibody epitopes and the putative fibrinogen-binding sites. Biochem. J. 274:1991;457-463.
13. Calvete J.J., Arias J., Alvarez M.V., Lopez M.M., Henschen A., Gonzalez-Rodriguez J. Further studies on the topography of human platelet glycoprotein IIb. Localization of monoclonal antibody epitopes and the putative glycoprotein IIa- and fibrinogen-binding regions. Biochem. J. 273:1991;767-775.
14. Takada Y., Puzon W. Identification of a regulatory region of integrin β1 subunit using activating and inhibiting antibodies. J. Biol. Chem. 268:1993;17597-17601.
15. Bajt M.L., Loftus J.C. Mutation of a ligand binding domain of β3 integrin. Integral role of oxygenated residues in αIIbβ3 (GPIIb-IIIa) receptor function. J. Biol. Chem. 269:1994;20913-20919.
16. Kamata T., Puzon W., Takada Y. Identification of putative ligand binding sites within I domain of integrin α2β1 (VLA-2 CD49b/CD29). J. Biol. Chem. 269:1994;9659-9663.
17. Irie A., Kamata T., Puzon-McLaughlin W., Takada Y. Critical amino acid residues for ligand binding are clustered in a predicted β-turn of the third N-terminal repeat in the integrin α4 and α5 subunits. EMBO J. 14:1995;5550-5556.
18. Kamata T., Puzon W., Takada Y. Identification of putative ligand-binding sites of the integrin α4β1 (VLA-4, CD49d/CD29). Biochem. J. 305:1995;945-951.
19. Huang C., Springer T.A. A binding interface on the I domain of lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J. Biol. Chem. 270:1995;19008-19016.
20. Kamata T., Wright R., Takada Y. Critical threonine and aspartic acid residues within the I domains of β2 integrins for interactions with intercellular adhesion molecule 1 (ICAM-1) and C3bi. J. Biol. Chem. 270:1995;12531-12535.
21. Schiffer S.G., Hemlers M.E., Lobb R.R., Tizard R., Osborn L. Molecular mapping of functional antibody binding sites of α4 integrin. J. Biol. Chem. 270:1995;14270-14273.
22. Kamata T., Irie A., Tokuhira M., Takada Y. Critical residues of integrin αIIb subunit for binding of αIIbβ3 (glycoprotein IIb-IIIa) to fibrinogen and ligand-mimetic antibodies (PAC-1, OP-G2, and LJ-CP3). J. Biol. Chem. 271:1996;18610-18615.
23. Munoz M., Serrador J., Sanchez-Madrid F., Teixido J. A region of the integrin VLA α4 subunit involved in homotypic cell aggregation and in fibronectin but not vascular cell adhesion molecule-1 binding. J. Biol. Chem. 271:1996;2696-2702.
24. Puzon-McLaughlin W., Takada Y. Critical residues for ligand binding in an I domain-like structure of the integrin β1 subunit. J. Biol. Chem. 271:1996;20438-20443.
25. Munoz M., Serrador J., Nieto M., Luque A., Sanchez-Madrid F., Teixido J. A novel region of the α4 integrin subunit with a modulatory role in VLA-4-mediated cell adhesion to fibronectin. Biochem. J. 327:1997;727-733.
26. Edwards C.P., Fisher K.L., Presta L.G., Bodary S.C. Mapping the intercellular adhesion molecule-1 and -2 binding site on the inserted domain of leukocyte function-associated antigen-1. J. Biol. Chem. 273:1998;28937-28944.
27. Burrows L., Clark K., Mould A.P., Humphries M.J. Fine mapping of inhibitory anti-α5 monoclonal antibody epitopes that differentially affect integrin-ligand binding. Biochem. J. 344:1999;527-533.
28. Kamata T., Liddington R.C., Takada Y. Interaction between collagen and the alpha(2) I-domain of integrin alpha(2)beta(1). Critical role of conserved residues in the metal ion-dependent adhesion site (MIDAS) region. J. Biol. Chem. 274:1999;32108-32111.
29. Zhang L., Plow E.F. Amino acid sequences within the alpha subunit of integrin alpha M beta 2 (Mac-1) critical for specific recognition of C3bi. Biochemistry. 38:1999;8064-8071.
30. Kapyla J., Ivaska J., Riikonen R., Nykvist P., Pentikainen O., Johnson M., Heino J. Integrin alpha(2)I domain recognizes type I and type IV collagens by different mechanisms. J. Biol. Chem. 275:2000;3348-3354.
31. Kamata T., Tieu K.K., Springer T.A., Takada Y. Amino acid residues in the αIIb subunit that are critical for ligand binding to integrin αIIbβ3 are clustered in the beta-propeller model. J. Biol. Chem. 276:2001;44275-44283.
32. Xiong Y., Zhang L. Structure-function of the putative I-domain within the integrin β2 subunit. J. Biol. Chem. 276:2001;19340-19349.
33. Emsley J., Knight C.G., Farndale R.W., Barnes M.J., Liddington R.C. Structural basis of collagen recognition by integrin alpha2beta1. Cell. 101:2000;47-56 The first report of the crystal structure of an integrin domain complexed with its ligand. The coordinates provide the template for transposing functional sites within αA-domains.
34. Shimaoka M., Xiao T., Liu J.H., Yang Y., Dong Y., Jun C.D., McCormack A., Zhang R., Joachimiak A., Takagi J.et al. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell. 112:2003;99-111.
35. Humphries M.J. Integrin cell adhesion receptors and the concept of agonism. Trends Pharmacol. Sci. 21:2000;29-32.
36. Bajt M.L., Goodman T., McGuire S.L. β2 (CD18) mutations abolish ligand recognition by I domain integrins LFA- 1 (αLβ2, CD11a/CD18) and MAC-1 (αMβ2, CD11b/CD18). J. Biol. Chem. 270:1995;94-98.
37. Beglova N., Blacklow S.C., Takagi J., Springer T.A. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat. Struct. Biol. 9:2002;282-287 This paper reports the NMR solution structure of the EGF3 repeat and the EGF2-EGF3 junction at the knee of the β2 subunit. The structure reveals the sites of activating mutations and stimulatory mAb epitopes within β2, and suggests a switchblade model of receptor opening that leads to activation.
38. Mould P., Askari J.A., Humphries M.J. Molecular basis of ligand recognition by integrin α5β1: specificity of ligand binding is determined by amino acid sequences in the second and third NH2-terminal repeats of the α subunit. J. Biol. Chem. 275:2000;20324-20336.
39. Puzon-McLaughlin W., Kamata T., Takada Y. Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding pocket in integrin alpha(IIb)beta(3). J. Biol. Chem. 275:2000;7795-7802.
40. Mould A.P., Askari J.A., Aota S., Yamada K.M., Irie A., Takada Y., Mardon H.J., Humphries M.J. Defining the topology of integrin α5β1- fibronectin interactions using inhibitory anti-α5 and anti-β1 monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the α5 subunit. J. Biol. Chem. 272:1997;17283-17292.
41. Mould A.P., Akiyama S.K., Humphries M.J. The inhibitory anti-β1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy. Evidence for allosteric inhibition of integrin function. J. Biol. Chem. 271:1996;20365-20374.
42. Newham P., Craig S.E., Clark K., Mould A.P., Humphries M.J. Analysis of ligand-induced and ligand-attenuated epitopes on the leukocyte integrin α4β1: VCAM-1, mucosal addressin cell adhesion molecule-1, and fibronectin induce distinct conformational changes. J. Immunol. 160:1998;4508-4517.
43. Mould A.P., Burrows L., Humphries M.J. Identification of amino acid residues that form part of the ligand-binding pocket of integrin α5β1. J. Biol. Chem. 273:1998;25664-25672.
44. Lee J.O., Bankston L.A., Arnaout M.A., Liddington R.C. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure. 3:1995;1333-1340.
45. Xiong J.P., Li R., Essafi M., Stehle T., Arnaout M.A. An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain. J. Biol. Chem. 275:2000;38762-38767 Either mutation or deletion of an invariant isoleucine residue in the C-terminal helix of the αM A-domain was shown to activate ligand binding constitutively. The isoleucine fits into a hydrophobic pocket in the closed conformation of the A-domain, but is exposed in the open form. This transition appears to be a key feature of the activation process as it is coupled to both structural rearrangements at the MIDAS (metal-ion-dependent adhesion site) site and a downward movement of the C-terminal α7 helix.
46. Huth J.R., Olejniczak E.T., Mendoza R., Liang H., Harris E.A., Lupher M.L., Wilson A.E., Fesik S.W., Staunton D.E. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc. Natl. Acad Sci. USA. 97:2000;5231-5236.
47. Mould AP, Barton SJ, Askari JA, McEwan PA, Buckley PA, Craig SE, Humphries MJ: Conformational changes in the integrin βA-domain provide a mechanism for signal transduction via hybrid domain movement. J Biol Chem 2003, in press.
48. 2+ results in an extended structure coupled to an outward swing of the hybrid domain at its junction with the βA-domain.
49. Mould A.P., Askari J.A., Barton S., Kline A.D., McEwan P.A., Craig S.E., Humphries M.J. Integrin activation involves a conformational change in the alpha 1 helix of the beta subunit A-domain. J. Biol. Chem. 277:2002;19800-19805.
50. Kallen J., Welzenbach K., Ramage P., Geyl D., Kriwacki R., Legge G., Cottens S., Weitz-Schmidt G., Hommel U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292:1999;1-9.